title: Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
abstract: BACKGROUND
  Electrophysiological evidence suggests a synergistic relationship between metabotropic (mGlu) and ionotropic (iGlu) glutamate receptors. The functional consequences of these interactions have not been investigated in neurodegenerative diseases such as in Parkinson's disease.
  
  
  OBJECTIVE
  The goals of this study are as follows: (1) to investigate the effects of 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and dizocilpine (MK-801), antagonists at metabotropic glutamate 5 (mGlu5) and NMDA receptors, respectively, on the akinetic syndrome observed in bilateral 6-OHDA-lesioned rats; (2) to investigate if the effects of MPEP were potentiated by co-treatment with a behaviorally inactive dose of MK-801; and (3) to investigate the effects of L-DOPA alone and in combination with MPEP on the akinetic syndrome observed in 6-OHDA-lesioned rats.
  
  
  METHODS
  The effects of the different treatments (single and co-treatment) administered for 3 weeks were measured in 6-OHDA-lesioned rats trained to release a lever rapidly after a visual stimulus onset in a simple reaction time task.
  
  
  RESULTS
  MPEP 0.75 mg/kg reversed the akinetic deficits produced by striatal dopamine depletion, while MPEP 0.375 mg/kg had no effect. Co-administration with MK-801 0.02 mg/kg, ineffective alone, failed to speed the recovery process of MPEP 0.75 mg/kg but revealed the anti-akinetic action of MPEP 0.375 mg/kg. L-DOPA 3 mg/kg alone had a potent anti-akinetic effect in 6-OHDA lesioned rats, and this effect was not potentiated by a subthreshold MPEP treatment.
  
  
  CONCLUSIONS
  These results support a critical role for mGlu5 receptor blockade in improving parkinsonian symptomatology either as a single treatment or in combination with low concentrations of L-DOPA and demonstrate an interaction between NMDA and mGluR5 in regulating these effects.
authors.affiliation: CNRS and Université de Provence, Marseille, France. Marianne.amalric@up.univ-mrs.fr
authors.forename: Nathalie
authors.initials: N
authors.lastname: Turle-Lorenzo
authors.forename: Nathalie
authors.initials: N
authors.lastname: Breysse
authors.forename: Christelle
authors.initials: C
authors.lastname: Baunez
authors.forename: Marianne
authors.initials: M
authors.lastname: Amalric
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004357:Drug Synergism; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000209:etiology*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: C578937:Grm5 protein, rat; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D007980:Levodopa; D016291:Dizocilpine Maleate; C121465:6-methyl-2-(phenylethynyl)pyridine
references.citation: J Neural Transm Suppl. 1992;38:65-89
references.pmid: 1491249
references.citation: Arch Neurol. 1991 Sep;48(9):977-81
references.pmid: 1835370
references.citation: J Neurosci. 2000 Nov 1;20(21):7871-9
references.pmid: 11050106
references.citation: Exp Neurol. 2002 Sep;177(1):252-64
references.pmid: 12429227
references.citation: J Neural Transm Park Dis Dement Sect. 1994;8(1-2):39-71
references.pmid: 7534462
references.citation: Br J Pharmacol. 1997 Mar;120(6):1007-14
references.pmid: 9134210
references.citation: Neuropharmacology. 1999 Oct;38(10 ):1493-503
references.pmid: 10530811
references.citation: Ann Neurol. 1990 Oct;28(4):539-46
references.pmid: 2252365
references.citation: Eur J Neurosci. 2002 Jan;15(1):120-32
references.pmid: 11860512
references.citation: J Pharmacol Exp Ther. 2003 Jul;306(1):116-23
references.pmid: 12660307
references.citation: Neurosci Biobehav Rev. 1997 Jul;21(4):437-46
references.pmid: 9195601
references.citation: Br J Pharmacol. 2000 Dec;131(7):1429-37
references.pmid: 11090117
references.citation: Neuroscience. 2001;106(3):579-87
references.pmid: 11591458
references.citation: J Neurosci. 2003 Sep 10;23 (23 ):8302-9
references.pmid: 12967992
references.citation: Brain. 1991 Feb;114 ( Pt 1B):513-25
references.pmid: 2004254
references.citation: Eur J Pharmacol. 2000 May 26;397(1):R1-2
references.pmid: 10844118
references.citation: Psychopharmacology (Berl). 2004 Sep;175(3):310-8
references.pmid: 15024550
references.citation: J Neurol Sci. 2000 Dec 1;181(1-2):98-103
references.pmid: 11099718
references.citation: J Pharmacol Exp Ther. 1999 Sep;290(3):1393-408
references.pmid: 10454519
references.citation: Brain Res. 1989 Apr 3;483(2):389-94
references.pmid: 2706530
references.citation: Neuropsychopharmacology. 2004 Jul;29(7):1259-69
references.pmid: 15010696
references.citation: J Neurosci. 2002 Jul 1;22(13):5669-78
references.pmid: 12097518
references.citation: Eur J Neurosci. 1998 Aug;10(8):2694-706
references.pmid: 9767399
references.citation: Eur J Pharmacol. 1990 Jul 17;182(3):611-2
references.pmid: 1977595
references.citation: Neuropharmacology. 2002 Dec;43(8):1199-209
references.pmid: 12527469
references.citation: Neurosci Biobehav Rev. 1997 Jul;21(4):455-68
references.pmid: 9195603
references.citation: Neurobiol Dis. 2002 Jul;10(2):165-86
references.pmid: 12127155
references.citation: Br J Pharmacol. 2001 Feb;132(4):799-806
references.pmid: 11181420
references.citation: Neuropharmacology. 2001 Sep;41(4):413-20
references.pmid: 11543761
references.citation: J Neurosci. 1987 Jul;7(7):2129-34
references.pmid: 3112323
references.citation: Science. 1992 Oct 23;258(5082):597-603
references.pmid: 1329206
references.citation: Eur J Neurosci. 1995 May 1;7(5):972-80
references.pmid: 7613632
references.citation: Exp Neurol. 1998 Jun;151(2):334-42
references.pmid: 9628768
references.citation: Trends Neurosci. 1990 Jul;13(7):281-5
references.pmid: 1695404
references.citation: J Neurosci. 1985 Jun;5(6):1513-21
references.pmid: 4009243
references.citation: Neuropharmacology. 1997 Feb;36(2):265-7
references.pmid: 9144665
references.citation: Annu Rev Pharmacol Toxicol. 1997;37:205-37
references.pmid: 9131252
references.citation: Behav Pharmacol. 1995 Aug;6(5 And 6):508-519
references.pmid: 11224358
references.citation: Psychopharmacology (Berl). 2004 Sep;175(2):179-88
references.pmid: 15007533
references.citation: J Neurosci. 2002 Nov 15;22(22):9679-86
references.pmid: 12427823
references.citation: Psychopharmacology (Berl). 2003 Jan;165(3):245-51
references.pmid: 12442203
references.citation: J Neurosci. 2001 Aug 15;21(16):5925-34
references.pmid: 11487615
references.citation: Annu Rev Biophys Biomol Struct. 1994;23:319-48
references.pmid: 7919785